$ACT Headlines Options remain limited for grow
Post# of 89346
Posted On: 01/29/2015 12:30:19 PM
$ACT Headlines
Options remain limited for growth-stock speculators 3:16 p.m. Jan. 22, 2015 - The Trading Deck
These unloved stocks may beat the S&P 500 again in 2015 10:56 a.m. Jan. 20, 2015 - Brett Arends
10 hated stocks your portfolio will love 6:01 a.m. Jan. 20, 2015 - Brett Arends
Actavis expects profit to beat expectations 9:44 a.m. Jan. 12, 2015 - Michael Calia
Drug trials, upgrades boost health-care sector 11:57 a.m. Jan. 8, 2015 - Russ Britt
10 stocks that can withstand a rocky 2015 12:31 p.m. Dec. 31, 2014 - The Trading Deck
Eight charts plot the year in finance 12:45 p.m. Dec. 30, 2014 - Ophir Gottlieb
Here are the best S&P 500 stocks and sectors of 2014 1:52 p.m. Dec. 29, 2014 - Philip van Doorn
2014 was the year that all predictions were wrong 11:29 a.m. Dec. 26, 2014 - Marek Fuchs
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Adamas' stock soars after dementia treatment approval 8:24 a.m. Dec. 24, 2014 - Tomi Kilgore
Second 2% S&P 500 spike signals strong bull trend 11:23 a.m. Dec. 19, 2014 - Michael Ashbaugh
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market 8:06 a.m. Today - Seeking Alpha
Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog 6:30 p.m. Jan. 28, 2015 - Zacks.com
Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst Blog 5:50 p.m. Jan. 28, 2015 - Zacks.com
Pfizer Sales Hit by Stronger Dollar 6:06 p.m. Jan. 27, 2015 - The Wall Street Journal Interactive Edition
Actavis to Buy Auden Mckenzie, Boost Generic Portfolio - Analyst Blog 6:00 p.m. Jan. 27, 2015 - Zacks.com
Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog 4:45 p.m. Jan. 27, 2015 - Zacks.com
Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog 3:20 p.m. Jan. 27, 2015 - Zacks.com
3 Stocks Dragging The Health Care Sector Downward 12:07 p.m. Jan. 27, 2015 - TheStreet.com
Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog 12:00 p.m. Jan. 27, 2015 - Zacks.com
Will Vertex (VRTX) Surprise with a Lower Loss in Q4? - Analyst Blog 11:20 a.m. Jan. 27, 2015 - Zacks.com
Citigroup Ponders How Results From Namenda Survey Might Affect Actavis 8:48 a.m. Jan. 27, 2015 - benzinga.com
Supernus Files Oxtellar XR Patent Infringement Lawsuit Again - Analyst Blog 4:00 p.m. Jan. 26, 2015 - Zacks.com
Actavis Surges Amid Acquisition Of Auden Mckenzie For £306 Million 10:45 a.m. Jan. 26, 2015 - benzinga.com
Actavis to Buy Auden Mckenzie 8:15 a.m. Jan. 26, 2015 - The Wall Street Journal Interactive Edition
UPDATE: Actavis Reports Purchase of Auden Mckenzie for £306M 6:34 a.m. Jan. 26, 2015 - benzinga.com
Pharmaceuticals Sector To See High Voltage Action in 2015 3:13 p.m. Jan. 23, 2015 - GuruFocus.com
Will Abiomed (ABMD) Outshine Q3 Earnings Estimates? - Analyst Blog 12:40 p.m. Jan. 23, 2015 - Zacks.com
3 Health Care Stocks Driving The Sector Higher 12:03 p.m. Jan. 23, 2015 - TheStreet.com
Will Pfizer (PFE) Beat Q4 Earnings Despite Generics? - Analyst Blog 11:30 a.m. Jan. 23, 2015 - Zacks.com
Top World Stocks Close In On Buy Points, New Highs 5:36 p.m. Jan. 22, 2015 - Investors Business Daily
Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC 5:30 p.m. Jan. 26, 2015 - BusinessWire - BZX
Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC 5:30 p.m. Jan. 26, 2015 - PR Newswire - PRF
Actavis to Acquire Auden Mckenzie for 306M GBP 7:30 a.m. Jan. 26, 2015 - PR Newswire - PRF
Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia 2:00 a.m. Jan. 20, 2015 - PR Newswire - PRF
Actavis Launches U.S. Generic Specialty Injectable Portfolio 8:00 a.m. Jan. 13, 2015 - PR Newswire - PRF
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom 8:35 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance 8:30 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:02 a.m. Jan. 12, 2015 - BusinessWire - BZX
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR 3:54 p.m. Jan. 6, 2015 - PR Newswire - PRF
Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine 2:00 a.m. Jan. 6, 2015 - PR Newswire - PRF
Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis 9:00 a.m. Dec. 29, 2014 - PR Newswire - PRF
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 1:15 p.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 8:00 a.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer 9:24 a.m. Dec. 22, 2014 - PR Newswire - PRF
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults 4:15 p.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 9:00 a.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition 7:30 a.m. Dec. 16, 2014 - PR Newswire - PRF
Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR 3:11 p.m. Dec. 15, 2014 - PR Newswire - PRF
Options remain limited for growth-stock speculators 3:16 p.m. Jan. 22, 2015 - The Trading Deck
These unloved stocks may beat the S&P 500 again in 2015 10:56 a.m. Jan. 20, 2015 - Brett Arends
10 hated stocks your portfolio will love 6:01 a.m. Jan. 20, 2015 - Brett Arends
Actavis expects profit to beat expectations 9:44 a.m. Jan. 12, 2015 - Michael Calia
Drug trials, upgrades boost health-care sector 11:57 a.m. Jan. 8, 2015 - Russ Britt
10 stocks that can withstand a rocky 2015 12:31 p.m. Dec. 31, 2014 - The Trading Deck
Eight charts plot the year in finance 12:45 p.m. Dec. 30, 2014 - Ophir Gottlieb
Here are the best S&P 500 stocks and sectors of 2014 1:52 p.m. Dec. 29, 2014 - Philip van Doorn
2014 was the year that all predictions were wrong 11:29 a.m. Dec. 26, 2014 - Marek Fuchs
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Adamas' stock soars after dementia treatment approval 8:24 a.m. Dec. 24, 2014 - Tomi Kilgore
Second 2% S&P 500 spike signals strong bull trend 11:23 a.m. Dec. 19, 2014 - Michael Ashbaugh
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market 8:06 a.m. Today - Seeking Alpha
Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog 6:30 p.m. Jan. 28, 2015 - Zacks.com
Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst Blog 5:50 p.m. Jan. 28, 2015 - Zacks.com
Pfizer Sales Hit by Stronger Dollar 6:06 p.m. Jan. 27, 2015 - The Wall Street Journal Interactive Edition
Actavis to Buy Auden Mckenzie, Boost Generic Portfolio - Analyst Blog 6:00 p.m. Jan. 27, 2015 - Zacks.com
Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog 4:45 p.m. Jan. 27, 2015 - Zacks.com
Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog 3:20 p.m. Jan. 27, 2015 - Zacks.com
3 Stocks Dragging The Health Care Sector Downward 12:07 p.m. Jan. 27, 2015 - TheStreet.com
Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog 12:00 p.m. Jan. 27, 2015 - Zacks.com
Will Vertex (VRTX) Surprise with a Lower Loss in Q4? - Analyst Blog 11:20 a.m. Jan. 27, 2015 - Zacks.com
Citigroup Ponders How Results From Namenda Survey Might Affect Actavis 8:48 a.m. Jan. 27, 2015 - benzinga.com
Supernus Files Oxtellar XR Patent Infringement Lawsuit Again - Analyst Blog 4:00 p.m. Jan. 26, 2015 - Zacks.com
Actavis Surges Amid Acquisition Of Auden Mckenzie For £306 Million 10:45 a.m. Jan. 26, 2015 - benzinga.com
Actavis to Buy Auden Mckenzie 8:15 a.m. Jan. 26, 2015 - The Wall Street Journal Interactive Edition
UPDATE: Actavis Reports Purchase of Auden Mckenzie for £306M 6:34 a.m. Jan. 26, 2015 - benzinga.com
Pharmaceuticals Sector To See High Voltage Action in 2015 3:13 p.m. Jan. 23, 2015 - GuruFocus.com
Will Abiomed (ABMD) Outshine Q3 Earnings Estimates? - Analyst Blog 12:40 p.m. Jan. 23, 2015 - Zacks.com
3 Health Care Stocks Driving The Sector Higher 12:03 p.m. Jan. 23, 2015 - TheStreet.com
Will Pfizer (PFE) Beat Q4 Earnings Despite Generics? - Analyst Blog 11:30 a.m. Jan. 23, 2015 - Zacks.com
Top World Stocks Close In On Buy Points, New Highs 5:36 p.m. Jan. 22, 2015 - Investors Business Daily
Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC 5:30 p.m. Jan. 26, 2015 - BusinessWire - BZX
Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC 5:30 p.m. Jan. 26, 2015 - PR Newswire - PRF
Actavis to Acquire Auden Mckenzie for 306M GBP 7:30 a.m. Jan. 26, 2015 - PR Newswire - PRF
Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia 2:00 a.m. Jan. 20, 2015 - PR Newswire - PRF
Actavis Launches U.S. Generic Specialty Injectable Portfolio 8:00 a.m. Jan. 13, 2015 - PR Newswire - PRF
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom 8:35 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance 8:30 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:02 a.m. Jan. 12, 2015 - BusinessWire - BZX
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR 3:54 p.m. Jan. 6, 2015 - PR Newswire - PRF
Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine 2:00 a.m. Jan. 6, 2015 - PR Newswire - PRF
Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis 9:00 a.m. Dec. 29, 2014 - PR Newswire - PRF
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 1:15 p.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 8:00 a.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer 9:24 a.m. Dec. 22, 2014 - PR Newswire - PRF
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults 4:15 p.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 9:00 a.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition 7:30 a.m. Dec. 16, 2014 - PR Newswire - PRF
Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR 3:11 p.m. Dec. 15, 2014 - PR Newswire - PRF
(0)
(0)